Fig. 3.

Treatment of MCC950 in Tgfbr1/Pten 2cKO mice SCCHN. a Schematic diagram represents the MCC950 delivery strategy in Tgfbr1/Pten 2cKO mice. Oral administration of tamoxifen was conducted consecutively for 5 days. Mice received 10 mg/kg MCC950 or control PBS 100 μl through intraperitoneal injection every day for the first three days and every other day for 20 consecutive days. Data are presented as mean ± SEM, n = 6. b Representative photos show that head and neck tumorigenesis was delayed after MCC950 treatment compared with the control group. c Gain weight to the mouse sacrifice deadline of MCC950 and control-treated mice. ns, not significant. d Tumor volume curve showed that MCC950 treatment delayed the growth of head and neck tumor (**P < 0.01)